Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1 mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependency of Tropifexor Metabolism
Wang-Lakshman, Lydia, Zhuang, Miao, Wang, Lai, Gu, Helen, Gu, Jessie, McNamara, Elizabeth, Walles, Markus, Woessner, Ralph, Camenisch, Gian P., Einolf, Heidi and Chen, Jin (2021) Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1 mg Dose of Tropifexor in Healthy Male Subjects and the Concentration Dependency of Tropifexor Metabolism. Drug metabolism and disposition, 49 (7). pp. 548-562. ISSN 1521-009X
Abstract
Tropifexor (NVP-LJN452) is a highly potent, selective, non-steroidal, non-bile acid farnesoid X receptor (FXR) agonist for the treatment of nonalcoholic steatohepatitis (NASH). Its absorption, metabolism, and excretion was studied following a 1-mg oral dose of [14C]tropifexor to four healthy male subjects. Mass balance was achieved with ~94% of the administered dose recovered in excreta through 312 hours collection period. Fecal excretion of tropifexor-related radioactivity played a major role (~65% of the total dose). Tropifexor reached a maximum blood concentration (Cmax) of 33.5 ng/mL with a median Tmax of 4 hours and was eliminated with a plasma elimination half-life (T1/2) of 13.5 hours. Unchanged tropifexor was the principal drug-related component found in plasma (~92% of total radioactivity). Two minor oxidative metabolites, M11.6 and M22.4, were observed in circulation. Tropifexor was eliminated predominantly via metabolism with >68% of the dose recovered as metabolites in excreta. Oxidative metabolism appeared to be the major clearance pathway of tropifexor. Metabolites containing multiple oxidative modifications and combined oxidation and glucuronidation were also observed in human excreta. The involvement of direct glucuronidation could not be ruled out, based on previous in vitro and nonclinical in vivo studies indicating its contribution to tropifexor clearance. The relative contribution of the oxidation and glucuronidation pathways appeared to be
dose-dependent upon further in vitro investigation. Due to these complexities and the instability of glucuronide metabolites in the gastrointestinal tract, the contribution of glucuronidation remained undefined in this study.
Item Type: | Article |
---|---|
Keywords: | ADME, FXR, Biotransformation, phase I & II metabolism, concentration-dependency |
Date Deposited: | 07 Sep 2021 00:45 |
Last Modified: | 07 Sep 2021 00:45 |
URI: | https://oak.novartis.com/id/eprint/43822 |